Seek truth from facts, competitive symbiosis
Zhengqing Group Debuts at the 12th World Federation of Chinese Medicine Societies Annual Conference on Traditional Chinese Medicine and Immunology; Zhengqing Fengtongning Becomes an Academic Focus.
Category:
Release time:
2025-11-12
From November 5 to 6, the 12th Annual Conference on Traditional Chinese Medicine Immunology, organized by the World Federation of Chinese Medicine Societies, was grandly held in Chongqing’s Liangjiang New Area. Top experts and scholars from the industry gathered to discuss innovative developments and clinical breakthroughs in the field of TCM immunology. Huang Yuming, Vice Chairman of Zhengqing Group, led the core team to attend the conference. Zhengqing Fengtongning, the group’s flagship product, has consistently drawn attention at several key academic sessions thanks to its solid clinical evidence and groundbreaking research achievements, making it one of the focal points of this prestigious event.
During the core session—the Academician and Expert Forum—held on the morning of November 6, the clinical value and scientific innovation of Zhengqing Fengtongning received prominent endorsement from authoritative experts. In his special report titled “Integrating Chinese and Western Medicine to Tackle Dryness,” Professor Liu Wei from the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, drawing on a wealth of clinical cases, provided an in-depth analysis of the mechanism of action and remarkable efficacy of Zhengqing Fengtongning in the treatment of Sjögren’s syndrome, offering valuable practical insights for the integrated Chinese-Western approach to managing this condition.
Even more noteworthy is that in his keynote speech, Academician Liu Liang of the Chinese Academy of Engineering, drawing on the classic TCM principle of "adapting treatment to the time," unveiled a groundbreaking scientific achievement by Zhengqing Fengtongning—the Class 2.2 new drug, Zhengqing Fengtongning Shichen Capsules. This innovative breakthrough not only serves as high recognition of Zhengqing Group’s deep commitment to the modernization of traditional Chinese medicine research and development, but also elevates the company’s product R&D to a strategic level that leads industry innovation, paving the way for a new approach to precision treatment in TCM.
During the sub-forum that afternoon, the academic influence of Zhengqing Fengtongning continued to gain momentum. At the special seminar on rheumatoid arthritis, numerous experts engaged in in-depth discussions centered around Zhengqing Fengtongning. Professor Pan Hudan systematically outlined the product’s clinical application experience and core value in the treatment of rheumatoid arthritis, providing strong support for its standardized clinical use. Meanwhile, Teacher Liu Peiyu presented a paper titled “Mechanism Study on How Sinomenine-Targeted B Cells Remodel IgG N-Glycosylation to Alleviate Rheumatoid Arthritis,” which delved into the molecular mechanisms underlying the action of sinomenine—the main active ingredient in Zhengqing Fengtongning—offering solid scientific evidence for its clinical efficacy and sparking extensive discussion and high recognition among the scholars present.
During the conference, Vice Chairman Huang Yuming engaged in in-depth discussions and exchanges with numerous influential experts and scholars in the field of rheumatology and immunology, including Academician Liu Liang, Professor Zhou Hua, Professor Fang Yongfei, and Professor Liu Yongqi, regarding the research, application, and promotion of the Zhengqing Fengtongning product. This strengthened the close collaboration between the company and leading academic authorities.
In addition to the academic exchanges, the specially designed booth set up by Zhengqing Group at the conference also became a major attraction, drawing numerous participating experts and scholars to stop by and seek information. On-site staff provided detailed explanations about Zhengqing Fengtongning’s R&D journey, clinical data, and innovative achievements, further deepening the academic community’s understanding of the product. During the event, more than 100 experts and scholars participated in a questionnaire survey on the research and clinical application of Zhengqing Fengtongning, actively sharing their usage experiences and offering valuable suggestions, thereby accumulating rich insights for the product’s ongoing optimization and promotion.
This appearance at the 12th Annual Conference on Traditional Chinese Medicine and Immunology organized by the World Federation of Chinese Medicine Societies represents an important opportunity for Zhengqing Group to showcase its scientific research strength and convey its academic value. It also provides a concentrated platform to highlight the clinical significance, academic leadership, and deep-rooted scientific innovation of Zhengqing Fengtongning. Moving forward, Zhengqing Group will continue to deepen its commitment to the modernization of traditional Chinese medicine, constantly enhancing product quality and efficacy, and providing higher-quality treatment options for rheumatic and immune disease patients worldwide. Through concrete actions, we will help propel traditional Chinese medicine onto the global stage and contribute even more “Zhengqing Power”!
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地